| Name | Neuropeptide Y (29-64), amide, human acetate |
| Description | Neuropeptide Y (29-64), amide, human acetate is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity. |
| In vitro | It is showed that Neuropeptide Y (29-64), amide, human acetate is able to protect cortical neurons from Aβ25-35?toxicity. 2 μM NPY abolishes the toxic effects of Aβ25-35?at 24 and 48 h. The same effect on neuronal survival is observed in neurons exposed to 1 μM and 0.5 μM Neuropeptide Y (29-64), amide, human acetate pretreatments. Pretreatment with Neuropeptide Y (29-64), amide, human acetate Increases NGF Synthesis, reduces NGF mRNA, and restores NGF release in cortical neurons exposed to Aβ35-25[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | NeuropeptideYReceptor | Neuropeptide Y Receptor | Neuropeptide Y , amide, human Acetate | neuropeptide Y (NPY) receptor | Neuropeptide Y (2964), amide, human acetate | Neuropeptide Y (29 64), amide, human acetate |
| Inhibitors Related | [Leu31,Pro34]-Neuropeptide Y (porcine) | Lu AA33810 | (S)-VU0637120 | Galanin (1-16), mouse, porcine, rat | SF 11 | GW438014A | M617 acetate | JNJ-31020028 | Galantide acetate | DF-1012 FA | M871 acetate | Pancreatic Polypeptide (human) acetate |
| Related Compound Libraries | Peptide Compound Library |